Vifor Pharma Drug Patent Portfolio
Vifor Pharma owns 1 orange book drug protected by 13 US patents Given below is the list of Vifor Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11123363 | Potassium-binding agents for treating hypertension and hyperkalemia | 08 Oct, 2033 | Active |
| US9492476 | Potassium-binding agents for treating hypertension and hyperkalemia | 08 Oct, 2033 | Active |
| US9925212 | Potassium-binding agents for treating hypertension and hyperkalemia | 08 Oct, 2033 | Active |
| US8337824 | Linear polyol stabilized polyfluoroacrylate compositions | 29 May, 2030 | Active |
| US8147873 | Methods and compositions for treatment of ion imbalances | 20 Jun, 2028 | Active |
| US8282913 | Ion binding polymers and uses thereof | 29 May, 2027 | Active |
| US8216560 | Ion binding polymers and uses thereof | 14 Mar, 2027 | Active |
| US7556799 | Ion binding polymers and uses thereof | 27 Feb, 2025 | Expired |
| US10485821 | Ion binding polymers and uses thereof | 30 Mar, 2024 | Expired |
| US8287847 | Ion binding polymers and uses thereof | 30 Mar, 2024 | Expired |
| US8475780 | Ion binding polymers and uses thereof | 30 Mar, 2024 | Expired |
| US8778324 | Ion binding polymers and uses thereof | 30 Mar, 2024 | Expired |
| US8889115 | Ion binding polymers and uses thereof | 30 Mar, 2024 | Expired |
Latest Legal Activities on Vifor Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Vifor Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Jun, 2024 | US8337824 |
|
Maintenance Fee Reminder Mailed
Critical
| 03 Jun, 2024 | US8287847 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Apr, 2024 | US8282913 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Jan, 2024 | US8216560 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2023 | US8147873 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 May, 2023 | US10485821 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 May, 2022 | US8889115 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Jan, 2022 | US8778324 |
| Post Issue Communication - Certificate of Correction | 25 Oct, 2021 | US11123363 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Sep, 2021 | US9925212 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 21 Sep, 2021 | US11123363 |
|
Recordation of Patent Grant Mailed
Critical
| 21 Sep, 2021 | US11123363 |
|
Email Notification
Critical
| 02 Sep, 2021 | US11123363 |
|
Issue Notification Mailed
Critical
| 01 Sep, 2021 | US11123363 |
| Dispatch to FDC | 17 Aug, 2021 | US11123363 |
Vifor Pharma Drug Patents' Oppositions Filed in EPO
Vifor Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 18, 2016, by Hexal Ag. This opposition was filed on patent number EP09748557A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP09748557A | Apr, 2016 | Teva Pharmaceutical Industries Ltd | Patent maintained as amended |
| EP09748557A | Apr, 2016 | Hexal AG | Patent maintained as amended |
Vifor Pharma's Family Patents
Vifor Pharma drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 29.6% of its total global patent coverage. Click
below to unlock the full patent family tree.
Vifor Pharma Drug List
Given below is the complete list of Vifor Pharma's drugs and the patents protecting them.
1. Veltassa
Veltassa is protected by 13 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11123363 | Potassium-binding agents for treating hypertension and hyperkalemia |
08 Oct, 2033
(8 years from now)
| Active |
| US9492476 | Potassium-binding agents for treating hypertension and hyperkalemia |
08 Oct, 2033
(8 years from now)
| Active |
| US9925212 | Potassium-binding agents for treating hypertension and hyperkalemia |
08 Oct, 2033
(8 years from now)
| Active |
| US8337824 | Linear polyol stabilized polyfluoroacrylate compositions |
29 May, 2030
(5 years from now)
| Active |
| US8147873 | Methods and compositions for treatment of ion imbalances |
20 Jun, 2028
(3 years from now)
| Active |
| US8282913 | Ion binding polymers and uses thereof |
29 May, 2027
(2 years from now)
| Active |
| US8216560 | Ion binding polymers and uses thereof |
14 Mar, 2027
(1 year, 10 months from now)
| Active |
| US7556799 | Ion binding polymers and uses thereof |
27 Feb, 2025
(2 months ago)
| Expired |
| US10485821 | Ion binding polymers and uses thereof |
30 Mar, 2024
(1 year, 1 month ago)
| Expired |
| US8287847 | Ion binding polymers and uses thereof |
30 Mar, 2024
(1 year, 1 month ago)
| Expired |
| US8475780 | Ion binding polymers and uses thereof |
30 Mar, 2024
(1 year, 1 month ago)
| Expired |
| US8778324 | Ion binding polymers and uses thereof |
30 Mar, 2024
(1 year, 1 month ago)
| Expired |
| US8889115 | Ion binding polymers and uses thereof |
30 Mar, 2024
(1 year, 1 month ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veltassa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List